Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review

• Main Authors: Meyer Jonathan M. MD (Author), Chepke Craig MD (Author), Bera Rimal B. MD (Author), Pérez-Rodríguez M. Mercedes MD, PhD (Author), Lundt Leslie MD (Author), Franey Ericha G. PhD (Author), Dhanda Rahul PhD, MA (Author), Benning Betsy MBA (Author), Bron Morgan PharmD, MS (Author), Yonan Chuck PharmD (Author)
• Formato: Libro
• Publicado: American Association of Psychiatric Pharmacists, 2023-10-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Introduction: Two vesicular monoamine transporter 2 (VMAT2) inhibitors are approved in the United States (US) for the treatment of tardive dyskinesia (TD). There is a paucity of information on the impact of VMAT2 inhibitor treatment on patient social and physical well-being. The study objective was...